Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

apceth Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic

Published: Wednesday, February 06, 2013
Last Updated: Wednesday, February 06, 2013
Bookmark and Share
Development of apceth’s first innovative “Advanced Therapy Medicinal Product” based on modified adult stem cells for cancer therapy.

As of January 2013 apceth has entered the second round of funding for the development of its first cancer therapeutic based on patient’s own modified adult mesenchymal stem cells (MSC) running under the portfolio name Agenmestencel-T.

In December 2012 apceth has successfully concluded the first 2.5-year round of funding through the Federal Ministry of Education and Research (BMBF) for the development of Agenmestencel-T as part of the Munich Biotech Cluster initiative “m4 Personalized Medicine and Targeted Therapies” (Cluster project PM5, FKZ: 16EX1021K).

The Munich Biotech Cluster comprises a rich network of biotech and pharma companies, research institutions and clinical centers in order to promote and expedite the creation of the future orientated personalized and targeted therapy strategies. As the winner of the second round of the “Leading-Edge Cluster Competition” in 2010 the Munich Biotech Cluster has at its disposal a considerable funds granted by BMBF and the Bavarian Government within its “m4 Personalized Medicine and Targeted Therapies” initiative for this ambitious aim.

The second round of funding through BMBF apceth was granted at the end of 2012 as part of the m4 Cluster initiative. With this apceth’s total approved budget for the development of Agenmestencel-T amounted to 4.7 million € within a period of less than five years between July 2010 and March 2015.

Agenmestencel-T is a highly innovative stem cell-based medicinal product for personalized therapy of advanced and/or metastatic cancers. With Agenmestencel-T apceth is committed to provide a novel cell-based cancer drug which will be custom-made for every single patient. Combining the stringent principles of pharmaceutical development with targeted biomarker-based strategies for patient stratification, apceth aims to create the cancer drugs of uppermost quality and safety, while identifying those cancer patients that can mostly benefit from this novel cell therapy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
Roundup Impacts Gene Expression
Study published on the impact of low-dose toxicity of Roundup weed-killer on gene expression profiles.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!